Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,835,501 protect, and when does it expire?

Patent ► Subscribe protects BELEODAQ and is included in one NDA.

This patent has thirty-six patent family members in twenty-six countries.

Summary for Patent: ► Subscribe

Title:	Pharmaceutical formulations of HDAC inhibitors
Abstract:	This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s):	Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee:	TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:	11/913,191
Patent Claim Types: see list of patent claims	Composition; Compound; Formulation; Dosage form; Device;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product
Spectrum Pharms	BELEODAQ	belinostat	POWDER;IV (INFUSION)	206256-001	Jul 3, 2014	RX	Yes	Yes	► Subscribe	► Subscribe	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

PCT Information
PCT Filed	May 11, 2006	PCT Application Number:	PCT/GB2006/001737
PCT Publication Date:	November 16, 2006	PCT Publication Number:	WO2006/120456

International Patent Family for Patent: ► Subscribe

Country	Document Number	Estimated Expiration
Norway	339954	► Subscribe
Norway	20076366	► Subscribe
Mexico	2007013938	► Subscribe
South Korea	101340824	► Subscribe
South Korea	20080016636	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview